Median Technologies has signed a contract with Sanofi for the interpretation and end-to-end management of medical images in a Phase II study on small cells lung cancer.
Subscribe to our email newsletter
Under the contract, Median will employ its LMS platform at all 65 investigator and independent review sites.
The aim of the project is to reduce reading variability and discordance issues in image interpretation, which are thought to impact clinical trial outcomes.
Using Median LMS, the sites will be able to conduct RECIST 1.1 criteria-based evaluations, while the end-to-end image management will be carried out through Median CTIS.
The real-time electronic imaging data transfer from investigator sites to independent review sites will allow the independent reviews to be processed faster and with a more efficient management of queries on missing or erroneous data.
Median Technologies Business Development vice president Jerome Windsor said their solutions increase the accuracy of data interpretation and also create new perspectives for pathology follow up, benefiting the patients.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.